Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination refers to the clinical co-administration of vaccines targeting five major serogroups of *Neisseria meningitidis* (A, B, C, W, and Y) along with paracetamol (acetaminophen). The meningococcal B vaccine (e.g., Bexsero) is a multicomponent vaccine containing recombinant proteins and outer membrane vesicles, while the meningococcal ACWY vaccine is a conjugate vaccine where capsular polysaccharides are linked to a carrier protein (such as CRM197 or tetanus toxoid). Paracetamol is administered prophylactically or therapeutically to manage the high rate of fever (pyrexia) specifically associated with the MenB vaccine, particularly in infants. This regimen is standard in several national immunization programs to provide broad protection against invasive meningococcal disease while mitigating common systemic adverse reactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meningococcal B vaccine + meningococcal ACWY conjugate vaccine + paracetamol.